<DOC>
	<DOCNO>NCT00801684</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety , tolerability single dose trospium inhalation powder ( TrIP ) administer subject chronic obstructive pulmonary disease ( COPD ) .</brief_summary>
	<brief_title>ALK27-001 : A Study Trospium Inhalation Powder ( TrIP ) Administered Subjects With COPD</brief_title>
	<detailed_description>This single-center , randomize , double-blind , cross-over , placebo-controlled study . Following screening , eligible subject randomize dosing sequence . Study subject receive total 5 single dos , separate 3- 14-day washout period . Doses A , B , C , D administer double-blind fashion , sequence generate 4-period Latin square design . The 4 dosing sequence : ABCD , BDAC , CADB , DCBA . Dose E administer open-label fashion final dose dose sequence subject . Subjects report clinic evening prior dose . Protocol assessment carry 24 hour postdose . Pulmonary function test ( via spirometry ) capture specified timepoints baseline well dose . Other efficacy safety outcome assess accord protocol . Blood sample perform assessment trospium concentration specify timepoints .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Respiratory Aspiration</mesh_term>
	<mesh_term>Trospium chloride</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<criteria>Male female COPD subject age 40 80 year Body mass index 18 35 Medically healthy ( COPD ) FEV1/FVC le equal 0.70 Current nonsmoker able abstain smoking least 8 hour postdose Within previous 6 month , demonstrate improvement FEV1 ( great equal 10 % ) 1 hour follow administration ipratropium bromide inhalation ( 4 puff ) Females childbearing potential must agree use acceptable method contraception duration study Asthma last 10 year Allergic rhinitis , atopy , cystic fibrosis , bronchiectasis , tuberculosis Bladder neck obstruction , include urinary retention know symptomatic prostatic hypertrophy control medication Narrow angle glaucoma Tachyarrhythmia Alcohol dependence illicit drug abuse within past year Using longterm oxygen therapy Female subject pregnant breastfeed Participating another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>COPD</keyword>
	<keyword>pulmonary</keyword>
	<keyword>inhalation</keyword>
</DOC>